A randomized, double-blind, parallel-group trial comparing Casodex [bicalutamide] 150mg once daily with placebo in patients with non-metastatic prostate cancer
Phase of Trial: Phase III
Latest Information Update: 17 Dec 2015
At a glance
- Drugs Bicalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 17 Dec 2015 Results from the observational arm published in the Annals of Oncology.
- 07 Jan 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.